Emergent BioSolutions awarded 10-year $121M BARDA contract

Emergent BioSolutions announced that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority, or BARDA, part of the Administration for Strategic Preparedness and Response, or ASPR, within the U.S. Department of Health and Human Services, or HHS, valued at up to a maximum of $704M, for advanced development, manufacturing scale-up, and procurement of Ebanga, a licensed treatment for Ebola virus disease, or EVD. The 10-year contract consists of a base period of performance with two option periods for advanced development valued at approximately $121M, and option periods for procurement of Ebanga treatment over five years valued at up to $583M. If all option periods are exercised, the total contract value will be valued at up to approximately $704M. Under the terms of the contract, Emergent will complete activities to advance the development of Ebanga treatment through post-licensure commitments, including the transfer of technology as part of manufacturing scale-up, submission of a supplemental Biologics License Application to the FDA, and completion of stability studies.